WEE1 and ocular melanoma: The results suggest that molecularly targeted agents, including protein kinase inhibitors such as afatinib and everolimus, and antibody preparations such as panitumumab, are more likely to induce OM than cell-killing antineoplastic agents such as 5-FU and methotrexate.